RespiratoryShijiazhuang Yiling Pharmaceutical synthesizes new LPAR1 antagonistsShijiazhuang Yiling Pharmaceutical Co. Ltd. has divulged new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists potentially useful for the treatment of pulmonary fibrosis.